Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.

Genet Med 2019 Jul 24. Epub 2019 Jul 24.

Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Purpose: Pathogenic variants affecting MLH1, MSH2, MSH6, and PMS2 cause Lynch syndrome and result in different but imprecisely known cancer risks. This study aimed to provide age and organ-specific cancer risks according to gene and gender and to determine survival after cancer.

Methods: We conducted an international, multicenter prospective observational study using independent test and validation cohorts of carriers of class 4 or class 5 variants. After validation the cohorts were merged providing 6350 participants and 51,646 follow-up years.

Results: There were 1808 prospectively observed cancers. Pathogenic MLH1 and MSH2 variants caused high penetrance dominant cancer syndromes sharing similar colorectal, endometrial, and ovarian cancer risks, but older MSH2 carriers had higher risk of cancers of the upper urinary tract, upper gastrointestinal tract, brain, and particularly prostate. Pathogenic MSH6 variants caused a sex-limited trait with high endometrial cancer risk but only modestly increased colorectal cancer risk in both genders. We did not demonstrate a significantly increased cancer risk in carriers of pathogenic PMS2 variants. Ten-year crude survival was over 80% following colon, endometrial, or ovarian cancer.

Conclusion: Management guidelines for Lynch syndrome may require revision in light of these different gene and gender-specific risks and the good prognosis for the most commonly associated cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41436-019-0596-9DOI Listing
July 2019
11 Reads
7.329 Impact Factor

Publication Analysis

Top Keywords

cancer risks
16
lynch syndrome
12
cancer risk
12
cancer
8
validation cohorts
8
carriers pathogenic
8
endometrial ovarian
8
mlh1 msh2
8
risks gene
8
variants caused
8
variants
6
pathogenic
5
trait high
4
sex-limited trait
4
merged providing
4
providing 6350
4
caused sex-limited
4
pathogenic msh6
4
follow-up yearsresults
4
51646 follow-up
4

References

(Supplied by CrossRef)

V Bonadona et al.
JAMA 2011

C Engel et al.
J Clin Oncol 2012

P Watson et al.
Int J Cancer 2008

HF Vasen et al.
J Clin Oncol 2001

M Aarnio et al.
Int J Cancer 1999

P Moller et al.
Gut 2018

P Moller et al.
Gut 2017

P Moller et al.
Gut 2017

T Seppala et al.
Hered Cancer Clin Pract 2017

C Engel et al.
Gastroenterology 2018

SW Broeke ten et al.
J Clin Oncol 2015

Similar Publications